From MarketBeat:

CEO Nadim Ahmed of Cullinan Oncology, Inc. sold 4,272 shares of the company’s stock on December 26th in a transaction valued at $39,473.28. Institutional investors have also recently modified their holdings in the company, with Vanguard Group, BlackRock Inc., and Franklin Resources Inc. growing their positions. Cullinan Oncology last released its quarterly earnings data on November 8th, with predictions for a post of -4.1 EPS for the current fiscal year. The company currently has a “Buy” rating among analysts and is set to release its lead candidate, CLN-081, an oral small molecule designed for non-small cell lung cancer patients.

In addition to CEO Nadim Ahmed’s stock sale, Cullinan Oncology has received attention from institutional investors, including CHI Advisors LLC and BlackRock Inc. The company’s performance on NASDAQ has seen shares trading up by $0.44, reaching $10.05.

This story was reviewed by MarketBeat’s editorial team prior to publication. For more information on stocks analysts are recommending, including Cullinan Oncology, visit MarketBeat’s website.



Read more: Cullinan Oncology, Inc. (NASDAQ:CGEM) CEO Nadim Ahmed Sells 4,272 Shares